NCT03585907 is a NA clinical trial of MAD in Alzheimer Disease, sponsored by Johns Hopkins University.

Who is sponsoring NCT03585907?

NCT03585907 is sponsored by Johns Hopkins University.

What drugs are being tested in NCT03585907?

Interventions in NCT03585907: MAD, MIND.

What condition does NCT03585907 study?

NCT03585907 studies Alzheimer Disease, Cognitive Impairment.

Is NCT03585907 still recruiting?

NCT03585907 is currently withdrawn. Last updated 3 October 2019.

Last reviewed 2019-10-03 · How we verify

NCT03585907

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility and Efficacy of Dietary Interventions for Older Adults With Subjective Cognitive Decline

Withdrawn NA Last updated 3 October 2019

What this trial tests

NA trial testing MAD in Alzheimer Disease. Withdrawn.

Timeline

2 September 2019

Primary endpoint
1 September 2021

1 September 2021

Quick facts

Lead sponsor	Johns Hopkins University
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Start date	2 September 2019
Primary completion	1 September 2021
Estimated completion	1 September 2021

Drugs / interventions tested

MAD
MIND

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →
Cognitive Impairment — all drugs for Cognitive Impairment →

Sponsor

Johns Hopkins University

Who can join

60 and older, any sex, with Alzheimer Disease or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to assess if/how dietary interventions (i.e., the Modified Atkins Diet (MAD) and/or the Mediterranean-Dietary Approaches to Stop Hypertension (DASH) Intervention for Neurodegenerative Delay (MIND)) might prevent, delay onset, alleviate symptoms, or otherwise alter the course of subjective cognitive decline (SCD) likely due to Alzheimer's disease (AD). We hypothesize that participants will tolerate both diets well and that the MAD will result in more favorable changes in cognition and other functioning.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease.
Perluigi M, Di Domenico F, Butterfield DA. · · 2024 · cited 154× · PMID 37843394 · DOI 10.1152/physrev.00030.2022
Nutrients in the Prevention of Alzheimer's Disease.
Cremonini AL, Caffa I, Cea M, Nencioni A, et al · · 2019 · cited 65× · PMID 31565158 · DOI 10.1155/2019/9874159
Management and Prevention of Neurodegenerative Disorders: Can Antioxidant-Rich Dietary Interventions Help?
Nagpal D, Nema S, Nagpal S, Pandey MM, et al · · 2025 · cited 2× · PMID 41008984 · DOI 10.3390/antiox14091078

Verify or expand the search:

Other trials of MAD

Trials testing the same drug.

NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT05435794 — Long-term Benefits of CPAP or MAD Treatment on the Sleep of OSAS Patients · recruiting
NCT01569022 — A Randomized Cross Over Trial of Two Treatments for Sleep Apnea in Veterans With Post-Traumatic Stress Disorder · NA · completed

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Johns Hopkins University trials

Trials by the same sponsor.

NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety · NA · not yet recruiting
NCT07532252 — Daridorexant for Alcohol Use Disorder · Phase 2 · not yet recruiting
NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea · Phase 1, PHASE2 · not yet recruiting
NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use · NA · not yet recruiting
NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03585907 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
Last refreshed: 3 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03585907.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing